PUBLISHER: DataM Intelligence | PRODUCT CODE: 1289773
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1289773
Global Carcinoid Syndrome Diarrhea Treatment Market - 2023-2030
Market Overview
The Global Carcinoid Syndrome Diarrhea Treatment Market reached US$ 3,514.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 7,275.6 million by 2030. The global carcinoid syndrome diarrhea treatment market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030).
Carcinoid syndrome diarrhea is a chronic condition that requires ongoing management and treatment to control symptoms and improve the quality of life for affected individuals. The goal of treatment is to regulate diarrhea, and minimize serotonin production and its effects, as well as other related symptoms. This may involve the use of drugs such as telotristat ethyl and somatostatin analogs as well as supportive care techniques.
Market Dynamics
Advancements in Treatment Options Are Boosting The Global Carcinoid Syndrome Diarrhea Treatment Market Growth.
Advancements in treatment options continue to evolve as ongoing research and clinical trials uncover new insights into CSD and neuroendocrine tumors. The development of targeted therapies and improved treatment options for carcinoid syndrome diarrhea has driven the market. For instance, the introduction of somatostatin analogs, telotristat ethyl, and other novel medications has provided more effective symptom control and management for patients.
Improved Diagnostic Techniques Are Providing The Global Carcinoid Syndrome Diarrhea Treatment Market With Prospective Growth Opportunities.
The development and refinement of diagnostic techniques have contributed to the increased diagnosis of noid syndrome diarrhea. Biomarker testing, such as measuring urinary 5-hydroxy indole acetic acid (5-HIAA) levels, plays a crucial role in identifying the presence of neuroendocrine tumors associated with noid syndrome diarrhea. Advanced imaging techniques, such as computed tomography scans and somatostatin receptor imaging, aid in the localization and assessment of tumors.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the carcinoid syndrome diarrhea treatment market. Several medical professionals switched to telemedicine and remote care solutions to reduce the danger of virus transmission and guarantee continuity of service. Healthcare specialists were able to examine carcinoid syndrome diarrhea patients remotely, offer advice, and modify treatment programs as necessary due to virtual consultations and telehealth technologies. The pandemic may have delayed or restricted some aspects of carcinoid syndrome diarrhea management, such as in-person operations or specialized testing, even while telemedicine made it easier to provide continuous care.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the carcinoid syndrome diarrhea treatment market is complex and multifaceted. Hospitals, clinics, and supply networks for medical equipment might all be affected by the conflict. This disturbance may have an impact on the accessibility and efficacy of carcinoid syndrome diarrhea therapies, making it more difficult for patients to obtain the required drugs and medical care.
Segment Analysis
The global carcinoid syndrome diarrhea treatment market is segmented based on therapy type, distribution channel, end-user, and region.
The Somatostatin Analog (SSA) Therapy Segment Is Expected To Hold A Dominant Position In The Market Over The Forecast Period.
The somatostatin analog (SSA) therapy segment accounted for the highest market share accounting for around 54.04% of the carcinoid syndrome diarrhea treatment market in 2022. For instance, in April 2022, Ipsen granted SERB the license to market Xermelo (telotristat ethyl) in Europe and other nations besides the US and Japan. When combined with somatostatin analog therapy, Xermelo is approved for the treatment of adults with carcinoid syndrome diarrhea that is not well controlled by SSA medication.
Geographical Analysis
Technological Advancements And Improvements In Carcinoid Syndrome Diarrhea Treatment Dominate the North American Region.
North America is expected to hold around 41.2% of the total market share throughout the forecast period. North America is at the forefront of technological advancements in healthcare. The region has access to state-of-the-art diagnostic tools, imaging techniques, and laboratory facilities, enabling accurate diagnosis and monitoring of carcinoid syndrome diarrhea. These advancements aid in treatment planning and assessment of treatment outcomes.
Competitive Landscape
The major global players in the market include: Novartis AG, Lexicon Pharmaceuticals, Ipsen Biopharmaceuticals, Pfizer Inc., Hutchison China MediTech Limited (Chi-Med), Progenics Pharmaceuticals, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., Helsinn Group, and Omega Laboratories Ltd. among others.
Why Purchase the Report?
- To visualize the global carcinoid syndrome diarrhea treatment market segmentation based on the therapy type, distribution channel, end-user, and region, and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of carcinoid syndrome diarrhea treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global carcinoid syndrome diarrhea treatment market report would provide approximately 61 tables, 57 figures, and 195 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Therapy Type
- 3.2. Snippet by Distribution Channel
- 3.3. Snippet by End User
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. The promising carcinoid syndrome diarrhea pipeline is driving the global carcinoid syndrome diarrhea treatment market growth.
- 4.1.2. Restraints
- 4.1.2.1. Lack of is hampering the growth of the global Carcinoid Syndrome Diarrhea Treatment market.
- 4.1.3. Opportunity
- 4.1.4. Increasing awareness about carcinoid syndrome diarrhea among patients,
- 4.1.5. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Unmet Needs
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers' Strategic Initiatives
- 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Therapy Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 9.1.2. Market Attractiveness Index, By Therapy Type
- 9.2. Chemotherapy*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Somatostatin Analog (SSA) Therapy
- 9.4. Others
10. By Distribution Channel
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Retail Pharmacy*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Hospital Pharmacy
- 10.4. Online Pharmacy
11. By End User
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.1.2. Market Attractiveness Index, By End User
- 11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Cancer Research Center
- 11.4. Ambulatory Surgery Centers
12. By Region
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.2.6.1. The U.S.
- 12.2.6.2. Canada
- 12.2.6.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.3.6.1. Germany
- 12.3.6.2. The U.K.
- 12.3.6.3. France
- 12.3.6.4. Italy
- 12.3.6.5. Spain
- 12.3.6.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.6.1. Brazil
- 12.4.6.2. Argentina
- 12.4.6.3. Rest of South America
- 12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.5.6.1. China
- 12.5.6.2. India
- 12.5.6.3. Japan
- 12.5.6.4. Australia
- 12.5.6.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
- 13.1. Competitive Scenario
- 13.2. Product Benchmarking
- 13.3. Company Share Analysis
- 13.4. Key Developments and Strategies
14. Company Profiles
- 14.1. Novartis AG*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. Lexicon Pharmaceuticals
- 14.3. Ipsen Biopharmaceuticals
- 14.4. Pfizer Inc.
- 14.5. Hutchison China MediTech Limited (Chi-Med)
- 14.6. Progenics Pharmaceuticals
- 14.7. Ipsen Pharma
- 14.8. Teva Pharmaceutical Industries Ltd.
- 14.9. Helsinn Group
- 14.10. Omega Laboratories Ltd.
LIST NOT EXHAUSTIVE
15. Appendix
- 15.1. About Us and Services
- 15.2. Contact Us
